Cytosorbents (NASDAQ:CTSO) Stock Crosses Above Two Hundred Day Moving Average - What's Next?

Cytosorbents Co. (NASDAQ:CTSO - Get Free Report)'s share price passed above its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of $1.04 and traded as high as $1.31. Cytosorbents shares last traded at $1.31, with a volume of 179,236 shares.

Analyst Upgrades and Downgrades

A number of research analysts have recently issued reports on the stock. D. Boral Capital restated a "buy" rating and issued a $10.00 price target on shares of Cytosorbents in a research report on Monday, January 13th. HC Wainwright restated a "neutral" rating and issued a $1.00 price target on shares of Cytosorbents in a research report on Monday, November 11th. Finally, StockNews.com assumed coverage on shares of Cytosorbents in a research report on Friday. They issued a "hold" rating on the stock. Two equities research analysts have rated the stock with a hold rating, two have issued a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, Cytosorbents presently has a consensus rating of "Moderate Buy" and a consensus price target of $4.67.

Cytosorbents Stock Performance

The company has a debt-to-equity ratio of 1.06, a quick ratio of 1.58 and a current ratio of 1.97. The stock's fifty day moving average is $0.99 and its two-hundred day moving average is $1.04. The firm has a market cap of $71.08 million, a price-to-earnings ratio of -3.61 and a beta of 0.61.

Institutional Trading of Cytosorbents

A number of large investors have recently modified their holdings of CTSO. Sargent Investment Group LLC increased its holdings in shares of Cytosorbents by 13.4% in the 3rd quarter. Sargent Investment Group LLC now owns 1,626,247 shares of the medical research company's stock worth $2,439,000 after acquiring an additional 192,747 shares during the period. Avenir Corp increased its holdings in shares of Cytosorbents by 4.0% in the 4th quarter. Avenir Corp now owns 3,093,946 shares of the medical research company's stock worth $2,815,000 after acquiring an additional 118,387 shares during the period. Raymond James Financial Inc. acquired a new stake in shares of Cytosorbents in the 4th quarter worth about $99,000. Millennium Management LLC acquired a new stake in shares of Cytosorbents in the 4th quarter worth about $30,000. Finally, Geode Capital Management LLC increased its holdings in shares of Cytosorbents by 7.5% in the 3rd quarter. Geode Capital Management LLC now owns 467,058 shares of the medical research company's stock worth $701,000 after acquiring an additional 32,415 shares during the period. Institutional investors and hedge funds own 32.87% of the company's stock.

About Cytosorbents

Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. Its flagship product is CytoSorb, an extracorporeal cytokine adsorber for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention, and treatment of perioperative complications, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant; and offers VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals.